This week, we will discuss SODaBIC trial: with ICU acidosis driven by multiple overlapping mechanisms, is bicarbonate infusion supported by robust evidence, or does it persist mainly out of habit rather than physiology?
FIND-CKD extends finerenone beyond diabetic kidney disease, showing slower eGFR decline and sustained albuminuria reduction in non-diabetic CKD. While the benefits are modest and cardiovascular effects remain uncertain, the trial opens the door to broader use of nsMRAs and raises important questions about combination therapy with SGLT2 inhibitors.
Can rivaroxaban improve cardiovascular outcomes in patients with advanced CKD.? Although vascular inflammation and thrombosis are at the heart of CV damage, anticoagulants have not previously shown benefits in CVD patients.
This week, NephJC will discuss whether obinutuzumab is ready to outperform tacrolimus in primary membranous nephropathy
What the hell is CHIP and why do I need to know about it?
Check out this rapid summary by the talented and creative Tiffany Caza!
Did you miss the last #NephJC? Check out this #TenTweetNephJC to catch up! pic.twitter.com/7oT34h2vzx
— Nephrology Jrnl Club (@NephJC) May 24, 2022
NSMC intern Mohamed Ibrahim created a beautiful visual abstract which simplifies the findings of CHIP study.
